In a groundbreaking study published in Nature Neuroscience, researchers from Inserm and the University of Bordeaux, in collaboration with the Université de Moncton in Canada, have established for the first time a causal link between mitochondrial dysfunction and cognitive symptoms in neurodegenerative diseases.
Read more: Neurodegenerative Diseases: Unlocking the Mitochondrial Connection
A new peer-reviewed review in Brain Network Disorders consolidates current evidence on clinical features, mechanisms, and laboratory biomarkers that can aid diagnosis and monitoring of anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, a leading form of autoimmune encephalitis in children and young adults.
Read more: Brain Network Disorders review maps emerging biomarkers for anti-NMDAR encephalitis
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for fremanezumab (Ajovy), making it the first anti-CGRP therapy approved for the prevention of episodic migraine in both adults and children aged 6–17 years weighing 45 kg or more. This marks a significant milestone in pediatric neurology, providing a much-needed treatment option for younger patients affected by this often-debilitating condition.
Read more: FDA Approves Fremanezumab for Pediatric Migraine Prevention
Researchers at MUSC Hollings Cancer Center have developed an artificial intelligence (AI) tool that can “read” doctors’ notes to identify the original source of cancers that spread to the brain, paving the way for more precise treatments.
Read more: AI Tool Reads Doctors’ Notes to Improve Brain Cancer Treatment
For most children, influenza (flu) typically causes uncomfortable but manageable symptoms such as fever, sore throat, and body aches. However, a rare complication known as influenza-associated acute necrotizing encephalopathy (ANE) can lead to devastating outcomes, including long-term neurological damage and death.
Read more: High Mortality Seen in Influenza-Associated Acute Necrotizing Encephalopathy in Children
Breakthrough in Neurodevelopmental Diagnostics
A pioneering artificial intelligence (AI) tool developed by researchers at Indiana University School of Medicine has demonstrated the ability to diagnose attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in children and adolescents within 15 minutes — and with up to 70% accuracy. The findings, published in Nature Scientific Reports on July 8, mark a promising advance in the rapid assessment of neurodevelopmental disorders (NDDs).
Read more: AI Tool Diagnoses ADHD and Autism in Just 15 Minutes, Shows 70% Accuracy
Screen time is often blamed for a range of problems in children – from rising depression and behavioural issues to disrupted sleep. Some high-profile voices, including Baroness Susan Greenfield, have even compared its potential impact on the developing brain to the early days of climate change: a looming threat not being taken seriously.
But new analysis suggests the science behind these concerns is far from settled. Researchers argue that much of the evidence is inconsistent, methodologically weak, or open to alternative explanations.
Read more: What screen time does to children's brains is more complicated than it seems
Chicago, July 2025 – New research from the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago reveals groundbreaking insights into how mitochondria, ancient bacterial descendants within our cells—may be key contributors to two distinct childhood neurological disorders: spinal muscular atrophy (SMA) and autism spectrum disorder (ASD).
Page 1 of 5
Terms & Conditions | Privacy statement | Disclaimer | Site Credits
All rights reserved, including rights for text and data mining and training of artificial intelligence technologies or similar technologies.